Quote from: Harley Quinn on December 21, 2016, 09:04:20 AMthen called back about my estrogen being "too high" for her liking. 475 pg/ml at my midcycle check.
Too high? Why?
Cancer. 2005 Feb 15;103(4):717-23."Patients with prostate carcinoma progressing after primary hormonal therapy received TDE (...) per 24 hours (administered as (...) per 24-hour patches replaced every 7 days)."
"The mean (+/-95% CI) serum estradiol level increased from 17.2
pg.mL (range, 14.8-19.6 pg/mL) to
460.7 pg/mL
(range, 334.6-586.7 pg/mL)."
"No change in factor VIII activity, F 1.2, or resistance to activated protein C was observed, whereas a modest
decrease in the protein S level was observed. CONCLUSIONS: In patients with APIC, TDE was well tolerated and produced a modest response rate, but
was not associated with thromboembolic complications or clinically important changes in several coagulation factors."
Median age of patients was 75 (49-91).J Urol. 2005 Aug;174(2):527-33; discussion 532-3.
Transdermal estradiol therapy for prostate cancer reduces
thrombophilic activation and protects against thromboembolism."Levels of VIIa and XIIa were unaffected by transdermal estradiol therapy. Although levels of TAT III were increased in some patients at 12 months, the increase was markedly less than that observed historically with equivalent doses of oral estrogens. Levels of the inhibitory and fibrinolytic factors including protein C, protein S, APC-R, TPA and PAI-1 remained stable. Reductions in F1+F2, fibrinogen and D-Dimer levels represented a normalization from increased levels to the physiological range."
"These results suggest that transdermal estradiol reduces thrombophilic activation in men with advanced prostate cancer, and protects against the risk of thrombosis."
My levels are several fold higher (1,000-4,000 pg/ml) and health markers remain normal, including clotting times. Has she checked c-reactive protein, clotting times, etc? If these check out fine, then why be concerned? Maybe you can bring this up with her.
Also,
Horm Metab Res. 1994 Sep;26(9):428-31."Thirteen osteopenic women received (...) estradiol valerate and (...) hydroxyprogesterone caproate by intramuscular injections once a week for 6 months (so called "pseudopregnancy")."
"
Six patients were peri- or postmenopausal (49.5 + 4.8 years of age, group A)"
"The duration of the therapy was 6, and in 4 patients 9 months"
"Estradiol increased from 34.8 +/- 7.5 pg/ml to
3226 +/- 393 pg/ml after 3 months and to 2552 +/- 254 pg/ml after 6 months, respectively, in group A."
"In group B estradiol increased from 27.8 +/- 6.5 pg/ml to
3028 +/- 728 after 3 and to 2491 +/- 684 pg/ml after 6 months."
"We have experience with therapeutic pseudopregnancy in about 200 patients with mammahypoplasia (Lauritzen 1992). Its rate of objective and subjective tolerance is excellent."
"
Investigations of lipids, liver enzymes and haemostasiology to be published later will show the absence of unwanted metabolic effects of this regimen."
"In conclusion, our data show, that the treatment (...) by means of high parenteral estrogen-progestogen depot injections is effective.
Virtually no side effects occurred. The therapy is well accepted by the patients."
Br J Obstet Gynaecol. 1990 Oct;97(10):917-21."There is some anxiety about the possible harmful sequelae of supraphysiological estradiol levels but
no data are currently available to show any deleterious effects of these levels on coagulation factors, blood pressure, glucose tolerance or the occurrences of endometrial or breast cancer (Hammond et al. 1974; Thom et id. 1978; Studd B Thom 1981; Armstrong 1988)."
"Increased levels of oestradiol may be beneficial, not only for their anti-depressant effect, but also in their effect upon bone density. The latter is greater after implant therapy than after oral therapy and is related to the greater plasma oestradiol levels achieved in women with implants. None of the 38 patients complained of alleged symptoms 01 oestrogen excess, such as breast tenderness, fluid retention or nausea."
"Supraphysiological oestradiol levels are an uncommon consequence of oestradiol implants (...). These high serum oestradiol levels were not associated with any deleterious effects and may be necessary for the control of symptoms in specific women"
"The mean serum oestradiol level of the 1388 women attending the clinic in 1988 was 767 pmol/l (range 78-2925 pmol/l), 66% had serum oestradiol levels <1000 pmol/l and 3% (38 women) had levels >1750 pmol/l (Fig 1)."
"The 15 women with PMS had a mean serum oestradiol of 2209 pmol/l (range 1760-2820 pmol/l). Their mean age at the start of treatment was 40 years (range 34-54) and the mean duration of therapy was 5.5 years (range 1-12)."
"The 23 menopausal women had a mean serum oestradiol of 2015 pmol/l (range 1785-2925 pmol/l). Their mean age was 46 years (range 29-58) and the mean duration of therapy was 4.5 years (range 1-10)."
2015-2209 pmol/L = 549 - 602 pg/ml
2820-2925 pmol/L = 768 - 797 pg/ml
Pregnancy levels are as high as 75,000 pg/ml.
Cancer Epidemiol Biomarkers Prev. 2003 May;12(5):452-6.http://cebp.aacrjournals.org/content/12/5/452.longhttp://www.ilexmedical.com/files/PDF/Estradiol_ARC.pdf "If conception occurs, estradiol levels continue
to rise, reaching levels of 1,000-5,000 pg/mL during the first trimester,
5,000-15,000 pg/mL during second trimester, and 10,000-40,000 pg/mL
during third trimester. 6-8"
And yet,
Ann Intern Med. 2005 Nov 15;143(10):697-706."Women with deep venous thrombosis or pulmonary embolism first diagnosed between 1966 and 1995, including women with venous thromboembolism during pregnancy or the postpartum period (defined as delivery of a newborn no more than 3 months before the deep venous thrombosis or pulmonary embolism event date, including delivery of a stillborn infant after the first trimester)."
« The relative risk (standardized incidence ratio) for venous thromboembolism among pregnant or postpartum women was 4.29 (95% CI, 3.49 to 5.22;P < 0.001), and the overall incidence of venous thromboembolism (absolute risk) was 199.7 per 100,000 woman-years. The annual incidence was 5 times higher among postpartum women than pregnant women (511.2 vs. 95.8 per 100,000), and the incidence of deep venous thrombosis was 3 times higher than that of pulmonary embolism (151.8 vs. 47.9 per 100,000). Pulmonary embolism was relatively uncommon during pregnancy versus the postpartum period (10.6 vs. 159.7 per 100,000). "
"Among pregnant women, the highest risk period for venous thromboembolism and pulmonary embolism in particular is during
the postpartum period." (When estrogen levels drop and are low)
Risk of venous thromboembolism during pregnancy: 0.1%
Risk of pulmonary embolism during pregnancy: 0.01%Also, you can show her that levels can actually get higher than yours during a woman's menstrual cycle (and as far as I know ciswomen aren't dying left and right)
Am J Med. 1995 Aug;99(2):119-22."normal postmenopausal plasma concentration less than 200 pmol/L (less than 54 pg/ml); normal premenopausal physiologic ranges: luteal 368 to 1,100 pmol/L (100 – 300 pg/ml),
midcycle 785 to 1,840 pmol/L (214 – 501 pg/ml), follicular 74 to 368 pmol/L (20 – 100 pg/ml) for estradiol"
Maturitas. 2005 Apr 11;50(4):266-74."Normal concentrations obtained via a fluorometric method, vary with the phase of the woman's menstrual cycle. During the follicular phase, they range from 35 to 184 pg/mL;
during the ovulatory phase, from 191 to 540 pg/mL; and during the luteal phase, from 40 to 228 pg/mL; at menopause, the 17β-estradiol level decreases to about 35 pg/mL. »
http://www.specialtylabs.com/clients/outreach/web/site/details.asp?tid=44312&cid=301&keyword=Female normal by day of the week relative to LH peak:
Mid Cycle: 38 - 649 pg/mL The American Journal of Otology
Issue: Volume 12(2), March 1991, p 119–121"The normal levels of plasma estradiol ranges from 25–75 pg/ml in the follicular phase, to
200–600 pg/ml at the midcycle peak, and 100–300 pg/ml in the luteal phase."
And finally, this...
Am J Obstet Gynecol. 1993 Dec;169(6):1549-53."As serum estradiol levels increased throughout each phase (
maximum mean estradiol 739.8 pg/ml)"
"Down-regulation of the fibrinolytic system was observed as estradiol levels increased.
However, thrombin formation did not change, thus suggesting that elevated circulating estradiol alone does not predispose to a thromboembolic event."
